atorvastatin has been researched along with zithromax in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Beaumont, K; Di, L; Maurer, TS; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Amsden, GW; Kuye, O; Wei, GC | 1 |
| Bate, A; Edwards, IR; Hägg, S; Strandell, J | 1 |
| Björnsson, ES | 1 |
2 review(s) available for atorvastatin and zithromax
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Clinical management of patients with drug-induced liver injury (DILI).
Topics: Acetylcysteine; Aged; Anti-Bacterial Agents; Anticholesteremic Agents; Atorvastatin; Azithromycin; Checklist; Chemical and Drug Induced Liver Injury; Female; Humans; Jaundice; Middle Aged; Pruritus; Symptom Assessment | 2021 |
1 trial(s) available for atorvastatin and zithromax
| Article | Year |
|---|---|
A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Atorvastatin; Azithromycin; Clarithromycin; Confidence Intervals; Drug Interactions; Female; Healthy Volunteers; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 2002 |
5 other study(ies) available for atorvastatin and zithromax
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Volume of Distribution in Drug Design.
Topics: Drug Design; Half-Life; Pharmacokinetics | 2015 |
Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Atorvastatin; Azithromycin; Databases, Factual; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Rhabdomyolysis; Simvastatin | 2009 |